58 results on '"Deterding K"'
Search Results
2. NK cell responses during direct-acting antiviral treatment of chronic hepatitis C virus infection
3. Six weeks of Sofosbuvir/Ledipasvir treatment of acute hepatitis C Virus genotype 1 monoinfection: Final results of the German HepNet Acute HCV IV Study
4. Sicherheit und Wirksamkeit interferonfreier antiviraler Therapien in der Behandlung fortgeschrittener HCV-assoziierter Leberzirrhose: Ergebnisse aus dem Deutschen Hepatitis C-Register (DHC-R)
5. Six weeks of sofosbuvir/ledipasvir (SOF/LDV) are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: The HepNet Acute HCV IV Study
6. Does response to antiviral therapy affect the clinical long-term outcome of hepatitis delta?
7. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies
8. Kinetic of Hepatitis B core-related antigen (HBcrAg) levels in chronic hepatitis B during NUC therapy
9. Eligibility and safety of sofosbuvir in a real-world single center cohort of patients with advanced cirrhosis, including decompensated cirrhosis
10. Serum biomarker profile can predict the outcome of acute HCV infection
11. Delayed early HCV RNA response during IFN-free therapy with sofosbuvir in interferon-ineligible patients with advanced cirrhosis
12. Clinical significance of drug-drug interactions during HCV therapy with sofosbuvir and simeprevir in comparison to first wave protease inhibitors
13. Interruption of nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B – A new concept to achieve HBsAg decline?
14. Large scale biomarker profiling reveals distinct cytokine and chemokine signatures distinguishing different acute and chronic hepatitis virus infections
15. Successful triple therapy of patients with chronic hepatitis C genotype 1 infection leads to significant improvement of non-invasive liver fibrosis tests
16. Response to entecavir treatment and evolution of HBV quasispecies in patients with failure to second line treatment with adefovir
17. Dominance of HCV in HBV/HCV co-infected patients is associated with lower quantitative HBsAg and higher serum IP-10 levels
18. Early on treatment detection of nucelos(t)ide analogue resistant minor variants of Hepatitis B virus (HBV) with ultra deep-pyrosequencing (UDPS) in chronic hepatitis B(CHB) patients
19. Long-term follow up of patients with Budd-Chiari syndrome and myeloproliferative disorders after liver transplantation
20. IL-28B Genotype is not associated with early HCV-RNA negativity in patients with symptomatic acute HCV infection
21. Factors predicting clinical endpoints in Hepatitis Delta: A retrospective-prospective single center study
22. Kosten einer leitliniengerechten Versorgung von Hepatitis-B-Patienten in Deutschland
23. Early versus delayed treatment of acute hepatitis C: Final results of the randomized controlled German HEP-NET acute HCV-III study
24. Unexpected increase of Hepatitis B Surface Antigen (HBsAg) levels during treatment with nucleos(t)ide analogous 12–24 months before virological breakthrough and resistance
25. The role of HDV in the natural history of the persistent HBV infection
26. Relevance of quantitative HBsAg (qHBsAg) during long-term treatment of chronic hepatitis B with nucleos(t)ide analogues (NUCs)
27. Telomerasemutationen sind mit der Entstehung von Leberzirrhose assoziiert
28. Adefovir treatment failure is not associated with low serum drug levels
29. Efficacy and safety of tenofovir disoproxil fumarate (TDF) monotherapy in a European multicenter cohort of nucleos(t)ide experienced patients with chronic hepatitis B virus (HBV)-infection
30. Management of hepatitis B virus infection: Impact of migrational background, education and household income
31. Begrenztes Wissen über Hepatitis B und schlechte Durchimpfung von Verwandten von Hepatitis B Patienten in Deutschland
32. Evaluation der Sicherheit und Verträglichkeit einer Tenofovir DF (TDF) Langzeit-Monotherapie bei Nukleos(t)id-Analoga-erfahrenen Patienten mit HBV Monoinfektion
33. Effektivität einer Tenofovir DF (TDF) Monotherapie in Abhängigkeit vorbestehender HBV-Resistenzmusterstationen bei Nukleosid/Nukleotid-Analoga-vorbehandelten Patienten
34. Klinische Bedeutung der HBs Antigen-Konzentration bei Patienten mit chronischer HBV/HCV-Koinfektion
35. Präsidentenposter: Early versus delayed treatment of acute hepatitis C: The German HEP-NET acute HCV-III study – a randomized controlled trial
36. Successful Treatment of Fulminant Hepatitis B during Pregnancy
37. The German Hep-Net Acute Hepatitis C Cohort: Impact of Viral and Host Factors on the Initial Presentation of Acute Hepatitis C Virus Infection
38. Role of BMI, age and sex for disease severity in acute hepatitis C: Analysis of 254 patients from the German Hep-Net acute HCV cohort
39. Incidence of alpha-fodrin antibodies in patients with chronic hepatitis C infection and sicca syndrome: a prospektive single-center study
40. FibroScan: Ursachen für schwankende hepatische Elastizitätswerte im Verlauf
41. Telomere shortening is a prognostic factor in chronic hepatitis C virus infection
42. A prospective multicenter pilot study to investigate the efficacy of pegylated Interferon-α2b and ribavirin in HBsAg+/HCV-RNA+ patients: The HEP-NET B/C coinfection trial
43. Verlauf einer chronischen HCV-Infektion im Verlauf einer akuten Delta Hepatitis
44. Long-term kinetics of quantitative HBsAg levels during successful oral antiviral therapy of chronic hepatitis B
45. Sustained HCV-RNA response and HBs-seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in an HCV/HBV-coinfected patient
46. Prävalenz der HBV-Genotypen in Mittel–und Osteuropa
47. Steroid Treatment for Severe Acute Cryptogenic Hepatitis
48. Massiver Ikterus unter Interferon/Ribavirinbehandlung bei Hepatitis C: behandeln oder abbrechen? – eine genetische Antwort
49. Klinischer und virologischer Verlauf einer akuten Hepatits A bei Patienten mit Hepatitis C: Geringes Risiko für eine fulminante Hepatitis und Suppression der HCV-Replikation
50. A still simple but improved Index to exclude fibrosis in chronic hepatitis C: Higher sensitivity of the APRI- Score by adding Serum-Cholesterinesterase
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.